Medicines such as OzemPIC and Wegovy can cut the risk of dementia significantly star-news.press/wp

Diabetes treatment and weight loss treatments such as OzemPIC and Wegovy, known as the GLP-1, can significantly reduce the risk of developing any type of dementia, according to a twiny of 26 clinical trials with more than 160,000 participants.

Treatments, which include drugs such as semaglote, liraglutide and Exenatide, have been linked to a slightly low dementia risk before, but this was based on noticeable studies looking at health records.

now, Katriona Redin At the University of Galway in Ireland and its colleagues, the results of random experiments were collected where a group of GLP-1 drugs were given to people with type 2 diabetes who have not yet been diagnosed with dementia or cognitive weakness, tested against the imaginary medicine. They found that taking these medications seemed to significantly reduce the risk of dementia or cognitive weakness during the lower follow -up periods for a period of six months.

“The golden standard will be one of the great random experience to answer this question, but this definitely adds another flow of evidence (to previous studies),” he says. Ziyad Al-Aly At the University of Washington University in St. Louis, Missouri, who has not participated in this research.

Diabetes may be DementiaTherefore, it was suggested that the mere control of blood sugar levels results in this preventive effect. For example, a Ticket by Jingshuan Qawah At the University of Florida and its colleagues, her colleagues indicate that a group of diabetes medications called SGLT2 inhibitors, which are less than blood sugar levels by helping the kidneys may reduce the risk of developing Alzheimer’s disease or relevant dementia, based on people’s health records.

But in the Reddin-controlled analysis, Sglt2 inhibitors were not linked to a low risk of dementia, indicating that the preventive effects of GLP-1 goes beyond merely controlling blood sugar.

Although the precise mechanism is unclear, these drugs have been linked to low inflammation, with Neuropathy It is increasingly recognized as a cause of dementia. By reducing chronic inflammation, they may be Surprisingly cell death in the brainRedin says.

It may protect GLP-1 medicines as well Cardiovascular problemslike Plaque accumulation In the arteries and High blood pressureWhich can cause dementia.

“All roads seem to lead to Rome. We can see multiple monitoring studies and now an analysis of studies controlled by the placebo that these drugs have an effect (anti-custom).”

Al-Aly emphasizes that we are not yet in a place where a person will be described at the risk of increasing the GLP-1 dementia to reduce his possibilities. But he also says that doctors may consider providing these medications on other drugs that reduce glucose for people with type 2 diabetes who are also at risk of cognitive decline, for example if they have a family history in this case. “This research will increase the doctor’s tendency to prescribe these medications,” he says.

Reddin notes that the follow -up period of at least six months was relatively short, and she says, “Large experiments must be done to study the effect of treatment to reduce glucose specifically on dementia and cognitive decrease.” This year is expected to conclude two clinical experiences looking for a treatment as a treatment for early Alzheimer’s disease this year.